The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Teprotumumab for Thyroid-Associated Ophthalmopathy
Open accessAbstract
BACKGROUND: Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy. METHODS: We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy. A total of 88 patients were randomly assigned to receive placebo or active drug administered intravenously once every 3 weeks for a total of eight infusions. The primary end point was the response in the study eye. This response was defined as a reduction of 2 points or more in the Clinical Activity Score (scores range from 0 to 7, with a score of ≥3 indicating active thyroid-associated ophthalmopathy) and a reduction of 2 mm or more in proptosis at week 24. Secondary end points, measured as continuous variables, included proptosis, the Clinical Activity Score, and results on the Graves' ophthalmopathy-specific quality-of-life questionnaire. Adverse events were assessed. RESULTS: In the intention-to-treat population, 29 of 42 patients who received teprotumumab (69%), as compared with 9 of 45 patients who received placebo (20%), had a response at week 24 (P<0.001). Therapeutic effects were rapid; at week 6, a total of 18 of 42 patients in the teprotumumab group (43%) and 2 of 45 patients in the placebo group (4%) had a response (P<0.001). Differences between the groups increased at subsequent time points. The only drug-related adverse event was hyperglycemia in patients with diabetes; this event was controlled by adjusting medication for diabetes. CONCLUSIONS: In patients with active ophthalmopathy, teprotumumab was more effective than placebo in reducing proptosis and the Clinical Activity Score. (Funded by River Vision Development and others; ClinicalTrials.gov number, NCT01868997 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smith, T. J., & Hegedüs, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510030 · Cited by 1,257
Self-citationSalvi, M., Vannucchi, G., Currò, N., Campi, I., Covelli, D., Dazzi, D., Simonetta, S., Guastella, C., Pignataro, L., Avignone, S., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3014 · Cited by 412
Self-citationIntravenous Glucocorticoids for Graves' Orbitopathy: Efficacy and Morbidity
Zang, S., Ponto, K. A., & Kahaly, G. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1962 · Cited by 379
Self-citationTsui, S., Naik, V., Hoa, N., Hwang, C. J., Afifiyan, N. F., Sinha Hikim, A., Gianoukakis, A. G., Douglas, R. S., & Smith, T. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.4397 · Cited by 372
Self-citationBartalena, L., Krassas, G. E., Wiersinga, W., Marcocci, C., Salvi, M., Daumerie, C., Bournaud, C., Stahl, M., Sassi, L., Veronesi, G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2389 · Cited by 370
Self-citationRandomized Controlled Trial of Rituximab in Patients With Graves' Orbitopathy
Stan, M. N., Garrity, J. A., Carranza Leon, B. G., Prabin, T., Bradley, E. A., & Bahn, R. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2572 · Cited by 369
Minireview: IGF, Insulin, and Cancer
Gallagher, E. J., & LeRoith, D. (2011) · Endocrinology · doi:10.1210/en.2011-0231 · Cited by 349
Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K.-P., Chawla, S. P., Toner, G. C., Maki, R. G., Meyers, P. A., Chugh, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0000 · Cited by 322
Terwee, C. B., Gerding, M. N., Dekker, F. W., Prummel, M. F., & Wiersinga, W. M. (1998) · British Journal of Ophthalmology · doi:10.1136/bjo.82.7.773 · Cited by 321
Marcocci, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3562 · Cited by 309
_, _., Wiersinga, W. M., Perros, P., Kahaly, G. J., Mourits, M. P., Baldeschi, L., Boboridis, K., Boschi, A., Dickinson, A. J., Kendall-Taylor, P., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02230 · Cited by 302
Self-citationPritchard, J., Han, R., Horst, N., Cruikshank, W. W., & Smith, T. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6348 · Cited by 295
Self-citationTRAMONTANO, D., CUSHING, G. W., MOSES, A. C., & INGBAR, S. H. (1986) · Endocrinology · doi:10.1210/endo-119-2-940 · Cited by 293
Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue
Feliciello, A., Ciullo, I., Fenzi, G. F., Bonavolontà, G., Porcellini, A., & Avvedimento, E. V. (1993) · The Lancet · doi:10.1016/0140-6736(93)91475-2 · Cited by 288
Smith, T. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002469 · Cited by 267
Self-citationSmith, T. J., & Hoa, N. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0716 · Cited by 256
Self-citationBahn, R. S., Dutton, C. M., Natt, N., Joba, W., Spitzweg, C., & Heufelder, A. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.3.4676 · Cited by 228
Terwee, C. B., Dekker, F. W., Mourits, M. P., Gerding, M. N., Baldeschi, L., Kalmann, R., Prummel, M. F., & Wiersinga, W. M. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01241.x · Cited by 202
Bahn, R. S. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.3.998 · Cited by 200
Kurzrock, R., Patnaik, A., Aisner, J., Warren, T., Leong, S., Benjamin, R., Eckhardt, S. G., Eid, J. E., Greig, G., Habben, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3220 · Cited by 196
TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis
Krieger, C. C., Place, R. F., Bevilacqua, C., Marcus-Samuels, B., Abel, B. S., Skarulis, M. C., Kahaly, G. J., Neumann, S., & Gershengorn, M. C. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1315 · Cited by 158
Self-citationDouglas, R. S., Gianoukakis, A. G., Kamat, S., & Smith, T. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.3281 · Cited by 157
Self-citationDouglas, R. S., Naik, V., Hwang, C. J., Afifiyan, N. F., Gianoukakis, A. G., Sand, D., Kamat, S., & Smith, T. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5768 · Cited by 148
Self-citationRamalingam, S. S., Spigel, D. R., Chen, D., Steins, M. B., Engelman, J. A., Schneider, C.-P., Novello, S., Eberhardt, W., Crinò, L., Habben, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.6799 · Cited by 134
Davies, T. F., & MORSHED, S. A. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1559633 · Cited by 133
Efficacy and Safety of Orbital Radiotherapy for Graves' Orbitopathy
Tanda, M. L., & Bartalena, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2758 · Cited by 104
Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies
Diana, T., Wüster, C. C., Kanitz, M., & Kahaly, G. J. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0478-9 · Cited by 84
Self-citationReactivation of Graves’ Orbitopathy after Rehabilitative Orbital Decompression
Baldeschi, L., Lupetti, A., Vu, P., Wakelkamp, I. M. M. J., Prummel, M. F., & Wiersinga, W. M. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.10.036 · Cited by 78
Pritchard, J., Tsui, S., Horst, N., Cruikshank, W. W., & Smith, T. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3564 · Cited by 74
Self-citationSisti, E., Coco, B., Menconi, F., Leo, M., Rocchi, R., Latrofa, F., Profilo, M. A., Mazzi, B., Albano, E., Vitti, P., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0712 · Cited by 58
The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy
Ma, H., Zhang, T., Shen, H., Cao, H., & Du, J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12228 · Cited by 48
Thyroid-Related Orbital Decompression Surgery: A Multivariate Analysis of Risk Factors and Outcomes
Wu, C. Y., Niziol, L. M., Musch, D. C., & Kahana, A. (2016) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000699 · Cited by 47
Is IGF-I Receptor a Target for Autoantibody Generation in Graves' Disease?
Smith, T. J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1004 · Cited by 32
Self-citation
Cited by
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Self-citationTeprotumumab for the Treatment of Active Thyroid Eye Disease
Douglas, R. S., Kahaly, G. J., Patel, A., Sile, S., Thompson, E. H. Z., Perdok, R., Fleming, J. C., Fowler, B. T., Marcocci, C., Marinò, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910434 · Cited by 752
Self-citationPatel, K. N., Yip, L., Lubitz, C. C., Grubbs, E. G., Miller, B. S., Shen, W., Angelos, P., Chen, H., Doherty, G. M., Fahey, T. J., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003580 · Cited by 541
Kaplon, H., Muralidharan, M., Schneider, Z., & Reichert, J. M. (2020) · mAbs · doi:10.1080/19420862.2019.1703531 · Cited by 429
Davies, T. F., Andersen, S., Latif, R., Nagayama, Y., Barbesino, G., Brito, M., Eckstein, A. K., Stagnaro-Green, A., & Kahaly, G. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0184-y · Cited by 398
Self-citation
Metadata
- Authors
- Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., Gigantelli, J. W., Couch, S. M., Shriver, E. M., Hayek, B. R., Hink, E. M., Woodward, R. M., Gabriel, K., Magni, G., & Douglas, R. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-05-04
- Volume
- 376
- Issue
- 18
- Pages
- 1748-1761
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2611131029
- Cited by
- 756
- References
- 33
- FWCI
- 37.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.